GSK 2654911A

Drug Profile

GSK 2654911A

Alternative Names: GSK2654911A

Latest Information Update: 04 Apr 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Influenza A virus H9N2 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H9N2 subtype

Most Recent Events

  • 12 Jun 2014 GlaxoSmithKline completes a phase I trial in Influenza-A virus infections in Canada and USA (NCT01659086)
  • 31 Aug 2012 Phase-I clinical trials in Influenza A virus infections in USA (IM)
  • 31 Aug 2012 Phase-I clinical trials in Influenza A virus infections in Canada (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top